Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Light-emitting Diodes (LED) Phototherapy for Hyperbilirubinemia of Term Newborn (DELF)

This study has been terminated.
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris Identifier:
First received: June 2, 2010
Last updated: December 10, 2012
Last verified: December 2012

June 2, 2010
December 10, 2012
January 2010
October 2011   (final data collection date for primary outcome measure)
Bilirubinemia [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01136577 on Archive Site
  • Evolution of bilirubinemia according to the device used [ Time Frame: 6, 12,24, 48, 72 hours ] [ Designated as safety issue: No ]
  • Hyperbilirubinemia rebound according to the device used [ Time Frame: 24 and 48 hours after discontinuation ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Light-emitting Diodes (LED) Phototherapy for Hyperbilirubinemia of Term Newborn
Comparison of Light-emitting Diodes (LED) Phototherapy Versus Fluorescent Lamps Phototherapy for Treatment of Hyperbilirubinemia in Term Newborn

Phototherapy is almost (beside exchange transfusion) the unique treatment for hyperbilirubinemia of the newborn. Its efficacy to decrease bilirubin level (because the light interacts with bilirubin at the skin level to transform it in water soluble products eliminated in urine and stools without liver metabolism) relies on the irradiance dispensed at the skin level by the device (in the 430-490nm range) and on the exposed surface of the baby. In the past years, technology of phototherapy devices moved from fluorescent lamps to LED, improving the amount of light energy emitted but on a smaller surface. The purpose of the study is to compare the efficacy of three ramps of phototherapy, one equipped with fluorescent tubes and two with LED (in a different technological settings) in the treatment of term (35 GW or more) healthy newborn suffering hyperbilirubinemia after 2days of life.

Term and healthy newborns on maternity wards in SAINT-ANTOINE hospital are checked everyday for jaundice with bilirubinometer JM-103®. If indicated (nomogram included in patient charts), a plasmatic bilirubin level is performed. If the baby is two days old or more with a bilirubin level indicating standard phototherapy (by opposition to intensive phototherapy), the parents are informed of the research protocol and after obtention of parental consent, the baby is included. The newborn is admitted in the neonatology unit and randomised in one of the three phototherapy devices group. Plasmatic bilirubin levels are checked at 6,12 and 24 and 48 hours of phototherapy. At 12 hours of phototherapy, a biological checking is performed to address the etiology of the jaundice. The next plasmatic bilirubin level is performed at 72h after inclusion. During phototherapy treatment the baby is continuously monitored. Phototherapy is stopped when bilirubin level is below 200µmol/l. If the bilirubin level is increasing under one of this ramps or does not decrease at H24, the baby will be immediately move on intensive phototherapy and participation at the research protocol interrupted. Twenty four hours after the end of phototherapy treatment, plasmatic bilirubin level is checked to confirm the end of jaundice and statement is made for jaundice origin. The total duration of participation of a baby at this study is 72 hours.

Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Device: Phototherapy
Phototherapy devices of ramp type placed over the incubator to treat with light in the 420-490nm range one face of the naked baby suffering jaundice.
Other Name: Phototherapy
  • Experimental: LEDDYBLOO®
    LEDDYBLOO® phototherapy device equipped with 20 at 30 blue and white LEDs
    Intervention: Device: Phototherapy
  • Experimental: Double BILITRON®
    Double BILITRON® phototherapy corresponding to two small ramps associated together each one equipped of 5 blue LEDS
    Intervention: Device: Phototherapy
  • Experimental: Futura®
    Future phototherapy device equipped with 8 fluorescent tubes
    Intervention: Device: Phototherapy

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2012
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Newborns in the hospital SAINT ANTOINE maternity wards
  • Gestational age of 35w or more
  • Healthy (no hypoxemia, no hypotonia, no abnormalities of thermic regulation, no infection or dehydration)
  • No foeto-maternal incompatibility in rhesus or kell group
  • With bilirubin level at 48h of 220µmoles/l or more if born at 38W or more or of 200µmoles/l or more if born between 35 and 38 W
  • Parental information done and signed consent obtained
  • Parents affiliated to social security

Exclusion Criteria:

  • Conjugated bilirubin level at 25µmol/l or more
  • Total bilirubin level over 300µmol/l indicating "intensive phototherapy"
  • Baby treated by phototherapy in the days before inclusion
  • Severe haemolytic disease with anemia below 14g/land or hyperbilirubinemia before 48h of life), rhesus or kell incompatibility
  • Parents who could not understand the information or sign the consent.
35 Weeks and older
Contact information is only displayed when the study is recruiting subjects
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Not Provided
Principal Investigator: Anne Cortey, Doctor APHP
Assistance Publique - Hôpitaux de Paris
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP